"The problem is that incentives are still not aligned. Health plans need to align incentives so that hospitals are not losing and not being counterproductive of the goals they are striving for, says Jan Berger, MD, MJ, President & CEO, Health Intelligence Partners and Editor-in-Chief, The American Journal of Pharmacy Benefits.
“Readmissions are an interesting area because if you think about it none of us want to be in the hospital, that’s just not a natural thing,” says Jan Berger, MD, MJ, President & CEO, Health Intelligence Partners and Editor-in-Chief, The American Journal of Pharmacy Benefits.
"The problem is that incentives are still not aligned. Health plans need to align incentives so that hospitals are not losing and not being counterproductive of the goals they are striving for." Dr. Berger also states that the combinations of technology and human interaction are important to reduce admissions.
This video interview was performed on June 21, 2012, at the America's Health Insurance Plans Institute 2012 in Salt Lake City, UT.
AI, GLP-1s Among Topics to Be Discussed During ASPC Annual Meeting
July 28th 2025The American Society for Preventive Cardiology (ASPC) Congress on Cardiovascular Disease Prevention features multiple sessions on different methods of treating and preventing cardiovascular disease, including through the use of artificial intelligence (AI) and glucagon-like peptide-1 (GLP-1) receptor agonists.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Across 8 Trials, Ruxolitinib Cream Shows Favorable Safety in Pediatric AD
July 25th 2025A poster at the Society for Pediatric Dermatology Annual Meeting presented an integrated safety analysis showing rare or no serious adverse events linked to topical Janus kinase inhibitor use in children with atopic dermatitis (AD).
Read More